Aesthetic Medicine: The Complete Guide
Injectable aesthetics encompass three distinct categories: neuromodulators (botulinum toxins that relax muscles), dermal fillers (materials that restore volume), and biostimulators (agents that trigger the body's own collagen production). The global injectable aesthetics market exceeds $16 billion, driven by expanding indications, the rapid growth of men's aesthetics, and a portfolio of FDA-approved products with decades of clinical data.
Navigate by Category
Each section covers a distinct class of injectable aesthetic treatment. Select a category to jump to its comparison table, or scroll for a complete overview.
Market & Regulatory Overview
The injectable aesthetics market surpasses $16 billion globally and continues to expand. Men now represent approximately 10–15% of all botulinum toxin and filler procedures in the United States. All neuromodulators and most major filler brands listed below carry FDA approval for specific cosmetic and/or therapeutic indications. Off-label use is common and legal when performed by licensed practitioners, though it falls outside the scope of FDA-evaluated safety and efficacy data.
Botulinum Toxin Comparison
Botulinum toxin type A products are FDA-approved neuromodulators that temporarily block acetylcholine release at the neuromuscular junction, reducing muscle activity responsible for dynamic wrinkles. Five products are currently available in the US market, each with distinct formulation characteristics.
Mechanism of Action
All botulinum toxin type A products cleave SNAP-25, a protein required for neurotransmitter vesicle fusion. This prevents acetylcholine release, producing temporary muscle paralysis at the injection site. The clinical effect — reduced wrinkle formation — typically becomes visible within 2 to 7 days and lasts 3 to 6 months depending on the product and individual metabolism.
Key Differences Between Products
Although all five products share the same core mechanism, they differ in molecular weight, complexing proteins (or lack thereof), diffusion characteristics, onset speed, and duration. These differences influence clinical decision-making regarding treatment area, dosing, and expected outcomes.
| Product | Key Characteristics | Evidence | FDA Status | Common Side Effects | Cost/Area |
|---|---|---|---|---|---|
| Botox OnabotulinumtoxinA (Allergan) |
|
✓✓✓✓✓ Extensive clinical — hundreds of RCTs, 20+ years of data | FDA-approved (2002, cosmetic glabellar lines) |
|
$300–$600 |
| Dysport AbobotulinumtoxinA (Galderma) |
|
✓✓✓✓✓ Extensive clinical — robust Phase 3 and post-market data | FDA-approved (2009, glabellar lines) |
|
$250–$550 |
| Xeomin IncobotulinumtoxinA (Merz) |
|
✓✓✓✓ Strong clinical — Phase 3 trials, non-inferiority to Botox | FDA-approved (2011, glabellar lines) |
|
$250–$550 |
| Jeuveau PrabotulinumtoxinA (Evolus) |
|
✓✓✓✓ Strong clinical — Phase 3 data, FDA-approved | FDA-approved (2019, glabellar lines) |
|
$250–$500 |
| Daxxify DaxibotulinumtoxinA (Revance) |
|
✓✓✓✓ Strong clinical — SAKURA Phase 3 trial program | FDA-approved (2022, glabellar lines) |
|
$400–$800 |
Summary:
All five FDA-approved botulinum toxin type A products produce comparable clinical outcomes for glabellar lines. Botox remains the most extensively studied. Dysport offers faster onset and broader diffusion. Xeomin eliminates complexing proteins. Jeuveau provides an aesthetics-only alternative at competitive pricing. Daxxify introduces a longer-duration option, with median effects lasting approximately 6 months. Product selection depends on treatment area, desired duration, patient history, and practitioner experience.
HA Fillers Guide
Hyaluronic acid (HA) fillers are the most widely used class of dermal fillers globally. HA is a naturally occurring glycosaminoglycan that attracts and retains water, providing volume, hydration, and structural support when injected into soft tissue. All major HA fillers are FDA-approved and reversible with hyaluronidase.
How HA Fillers Work
HA fillers consist of cross-linked hyaluronic acid gel. The degree of cross-linking (measured as G prime or cohesivity) determines the filler's firmness, lift capacity, and longevity. Higher G prime products are used for volumization and structural support (cheeks, chin, jawline), while lower G prime products are suited for superficial lines and lip augmentation.
| Product Line | Key Characteristics | Evidence | FDA Status | Common Risks | Cost/Syringe |
|---|---|---|---|---|---|
| Juvederm Collection Allergan — Vycross & Hylacross technology |
|
✓✓✓✓✓ Extensive clinical — multiple Phase 3 programs, post-market surveillance | FDA-approved (multiple indications: lips, cheeks, NLF, chin) |
|
$500–$900 |
| Restylane Family Galderma — NASHA & XpresHAn technology |
|
✓✓✓✓✓ Extensive clinical — first HA filler FDA-approved in US (2003) | FDA-approved (NLF, lips, cheeks, hands, chin) |
|
$450–$850 |
| RHA Collection Revance — Resilient Hyaluronic Acid |
|
✓✓✓✓ Strong clinical — FDA-approved, European data since 2015 | FDA-approved (2021, dynamic facial wrinkles and folds) |
|
$500–$800 |
| Belotero Balance Merz — CPM (Cohesive Polydensified Matrix) |
|
✓✓✓✓ Strong clinical — FDA-approved, well-studied in Europe | FDA-approved (2011, moderate-to-severe NLF) |
|
$450–$750 |
Summary:
HA fillers provide immediate, reversible volume restoration with an extensive safety record. Product selection depends on the treatment zone, desired longevity, and tissue plane. Juvederm Voluma offers the longest FDA-studied duration (up to 24 months in cheeks). Restylane Kysse and RHA products are optimized for dynamic movement areas. Belotero excels in superficial, fine-line correction. All HA fillers can be dissolved with hyaluronidase in the event of complications or patient dissatisfaction.
Biostimulatory Fillers
Biostimulatory fillers work differently from HA products: rather than simply filling volume, they trigger the body's own collagen production over weeks to months. Results develop gradually and can last significantly longer than traditional fillers — often 2 to 5 years.
How Biostimulators Work
These products provide an initial scaffold or inflammatory stimulus that activates fibroblasts to produce new type I and type III collagen. The carrier material (PLLA microspheres, CaHA microspheres, or PCL) is gradually absorbed, leaving behind the patient's own collagen matrix. This mechanism produces results that appear natural but require multiple treatment sessions and patience.
| Product | Key Characteristics | Evidence | FDA Status | Common Risks | Cost/Session |
|---|---|---|---|---|---|
| Sculptra Poly-L-lactic acid (PLLA) — Galderma |
|
✓✓✓✓ Strong clinical — FDA-approved, 10+ years post-market data | FDA-approved (2004 HIV lipoatrophy; 2009 cosmetic) |
|
$700–$1,200 |
| Radiesse Calcium hydroxylapatite (CaHA) — Merz |
|
✓✓✓✓ Strong clinical — FDA-approved, extensive clinical use | FDA-approved (2006, NLF and volume loss; hands 2015) |
|
$650–$1,000 |
| Ellanse Polycaprolactone (PCL) — Sinclair |
|
✓✓✓ Early clinical — CE-marked, not FDA-approved; growing international data | CE-marked (Europe); not FDA-approved in US |
|
$600–$1,200 |
| Renuva Allograft adipose matrix — Musculoskeletal Transplant Foundation |
|
✓✓ Limited human — registered as tissue product, not a drug; early clinical evidence | FDA-registered tissue product (361 HCT/P); not a drug approval |
|
$800–$2,000 |
Summary:
Biostimulatory fillers offer longer-lasting results than HA products by leveraging the body's collagen synthesis pathways. Sculptra and Radiesse are FDA-approved with extensive clinical histories. Ellanse provides tunable duration but is not available in the US. Renuva represents an emerging category using allograft tissue. The primary trade-off with biostimulators is irreversibility — unlike HA fillers, these products cannot be dissolved enzymatically, making proper injection technique and conservative treatment planning critical.
PDO Threads
Polydioxanone (PDO) threads are absorbable sutures inserted beneath the skin to provide mechanical lifting and stimulate collagen production. Originally developed for surgical suturing, PDO threads have been adapted for minimally invasive facial and body rejuvenation.
Thread Types and Mechanisms
PDO threads dissolve over 6 to 8 months, but the collagen scaffold they induce can maintain results for 12 to 18 months. Thread selection depends on the treatment goal: mono threads improve skin texture and tightening; cog (barbed) threads provide mechanical lift for sagging tissue; screw threads create localized volume.
| Thread Type | Key Characteristics | Evidence | Status | Common Risks | Cost/Session |
|---|---|---|---|---|---|
| Mono Threads Smooth PDO for skin rejuvenation |
|
✓✓ Limited human — small studies, mostly case series | FDA-cleared (510(k) for absorbable sutures) |
|
$500–$1,500 |
| Cog / Barbed Threads Barbed PDO for mechanical lifting |
|
✓✓✓ Early clinical — RCTs emerging; widely used internationally | FDA-cleared (510(k)); specific brands: NovaThreads, Mint PDO |
|
$1,500–$4,500 |
| Screw Threads Twisted PDO for volume effect |
|
✓✓ Limited human — case series and practitioner reports | FDA-cleared (as absorbable suture material) |
|
$800–$2,000 |
Summary:
PDO threads occupy a middle ground between dermal fillers and surgical facelifts. They provide modest lifting and skin tightening through mechanical support and collagen induction. Cog threads deliver the most noticeable lift, while mono and screw threads primarily improve skin quality. Results are temporary (12–18 months) and less dramatic than surgical intervention. Thread procedures require practitioner expertise in facial anatomy to minimize risks of asymmetry, migration, and nerve injury. PDO threads are FDA-cleared as absorbable suture materials; their cosmetic lifting applications represent off-label use of the cleared device.
PRP & PRF
Platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) are autologous blood-derived preparations used in aesthetic medicine for skin rejuvenation, hair restoration, and as natural bio-fillers. Because they use the patient's own blood, allergic reactions are essentially eliminated.
PRP vs PRF: Key Differences
PRP is produced by centrifuging anticoagulated blood to concentrate platelets and growth factors. PRF (also called injectable PRF or i-PRF) uses a slower spin without anticoagulants, producing a fibrin matrix that releases growth factors more slowly over 10 to 14 days. PRF also contains leukocytes, which may enhance tissue regeneration.
| Product | Key Characteristics | Evidence | Status | Common Risks | Cost/Session |
|---|---|---|---|---|---|
| PRP Platelet-Rich Plasma |
|
✓✓✓ Early clinical — multiple RCTs for hair and skin; variable protocols | FDA-cleared devices for preparation; PRP itself not FDA-approved as a drug |
|
$500–$1,500 |
| PRF / i-PRF Platelet-Rich Fibrin (injectable) |
|
✓✓ Limited human — newer than PRP; fewer controlled trials | Autologous blood product; regulated as medical procedure, not a drug |
|
$600–$1,500 |
| EZ-Gel / Bio-Filler PRF + albumin gel (autologous filler) |
|
✓ Mostly preclinical — very limited published data; technique is new | No specific FDA clearance; performed as autologous procedure |
|
$700–$2,000 |
Summary:
PRP and PRF harness the patient's own platelets and growth factors for tissue regeneration. PRP has the largest evidence base, particularly for androgenetic alopecia and skin rejuvenation. PRF offers sustained growth factor release and is gaining traction as both a standalone treatment and a combination therapy. EZ-Gel represents an emerging technique to create autologous fillers, though published evidence remains limited. The primary advantages of platelet-based therapies are biocompatibility and minimal allergy risk; the primary limitations are variable outcomes, the need for multiple sessions, and lack of standardized preparation protocols across providers.
Filler Safety
Injectable aesthetic procedures carry real risks that range from minor bruising to rare but serious complications including vascular occlusion and tissue necrosis. Understanding injection anatomy, recognizing complications early, and knowing emergency protocols are essential components of safe practice.
Vascular Occlusion
Vascular occlusion is the most serious complication of dermal filler injection. It occurs when filler material is inadvertently injected into or compresses a blood vessel, blocking blood flow to downstream tissue. If not treated promptly, this can result in skin necrosis or, in the rarest and most severe cases, blindness from retinal artery occlusion.
- High-risk zones: Glabella, nasal tip, nasolabial folds, temples, and infraorbital region
- Warning signs: Immediate blanching, severe pain disproportionate to injection, dusky discoloration, reticulated (net-like) skin pattern
- Incidence: Estimated at 1 in 6,000 to 1 in 40,000 filler procedures depending on the area treated
Hyaluronidase: The Safety Net
Hyaluronidase (Hylenex) is an enzyme that rapidly dissolves hyaluronic acid fillers. It is the primary emergency treatment for HA filler-related vascular occlusion and should be immediately available wherever HA fillers are injected.
- Mechanism: Cleaves glycosidic bonds in hyaluronic acid, dissolving the filler within minutes to hours
- Emergency dosing: 200–600 units injected into and around the affected area; may be repeated every 60–90 minutes
- Limitation: Effective only for HA fillers; cannot dissolve Sculptra, Radiesse, PMMA, or silicone
- Allergy risk: Hyaluronidase itself can cause allergic reactions; skin testing is recommended when time permits
Injection Anatomy Considerations
Safe injection requires detailed knowledge of facial vascular anatomy, including the locations of the angular artery, dorsal nasal artery, supratrochlear and supraorbital arteries, and the ophthalmic artery. The use of blunt-tip cannulas (vs sharp needles) in high-risk areas has been associated with reduced vascular complication rates in observational studies, though the evidence is not definitive.
- Aspiration: Drawing back on the syringe before injection to check for blood return; widely recommended though sensitivity is debated
- Cannula vs needle: Cannulas may reduce vascular puncture risk but do not eliminate it
- Injection speed: Slow, low-pressure injection with small bolus volumes reduces risk
Other Complications
- Infection: Bacterial biofilm can form around filler material, causing delayed nodules weeks to months after injection. Treatment typically requires antibiotics and may require filler dissolution or surgical drainage.
- Granulomas: Foreign body reactions that present as firm nodules, most common with permanent or semi-permanent fillers (PMMA, silicone). Can occur months to years post-injection.
- Migration: Filler material moving from the original injection site over time, particularly with repeated high-volume lip or under-eye treatments.
- Delayed hypersensitivity: Immune-mediated reactions that can appear weeks to months after injection, sometimes triggered by illness or vaccination. More common with biostimulatory fillers.
Summary:
Injectable aesthetic procedures have a strong overall safety record when performed by trained practitioners with appropriate anatomical knowledge. The most critical safety factor is vascular awareness — knowing danger zones, recognizing occlusion early, and having hyaluronidase readily available for HA filler emergencies. Patients should verify that their injector is a licensed medical professional with specific training in facial anatomy and filler injection technique. Non-HA fillers carry the additional consideration of irreversibility, making conservative treatment volumes and proper injection depth essential.
The information on this page is provided for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. No doctor-patient relationship is created by reading this content.
Products described on this page include FDA-approved medical devices and drugs, CE-marked products, off-label applications, and emerging techniques with limited clinical evidence. The inclusion of any product or procedure does not imply endorsement or a recommendation that it is safe or appropriate for any individual.
Always consult a licensed healthcare provider before undergoing any injectable aesthetic procedure. All injections carry risks including infection, allergic reaction, vascular compromise, and other complications. Outcomes vary based on individual anatomy, injector skill, and product selection.
Evidence descriptions, regulatory statuses, and cost ranges reflect publicly available data and reported US pricing. Actual costs vary by provider, geographic region, volume of product used, and treatment complexity.